Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Kína2. fázis

A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

A legfontosabb adatok

Ki végzi
AstraZeneca
Hol
Anyang, Beijing, Changsha, Chengdu, Chizhou, Haikou, Hefei, Hohhot, Jinan, Jinhua, Jining, Kunming, Langfang, Linhai, Liuzhou, Nanchang, Nanning, Shanghai, Shenyang, Taicang, Taizhou, Wenzhou, Xinxiang, Xuzhou, Zaozhuang, Zhangzhou, Zhengzhou, Zhuzhou és Zibo (Kína)Mind a 29 helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
84 fő, tervezett
Kezdés
2026. jún. 24.
Várható befejezés
2028. jún. 6.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • AZD0292
  • Placebo
A regiszteradat frissítve
2026. október 8.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for Chinese adults with bronchiectasis (widened airways in the lungs) whose airways keep carrying the germ Pseudomonas aeruginosa (PsA). It tests whether AZD0292 helps prevent flare-ups.

Életkor
18 years and older
Nem
All sexes
A betegség stádiuma
Bronchiectasis confirmed by a CT scan in at least 1 lobe. At least 2 moderate or at least 1 severe flare-up needing antibiotics in the past 12 months. No flare-up for 4 weeks before joining. Lung test FEV1 at least 25% of predicted. Weight at least 35 kg (77 lb).
Korábbi kezelés
People must be on standard care for bronchiectasis. People who had treatment to clear PsA but still carry it can join. Long-term anti-PsA antibiotics, macrolides or DPP-1 inhibitors started within the past 3 months are not allowed.
Biomarker vagy leletérték
PsA found (PCR or culture) in an airway sample at least once in the past 24 months, and PsA found by culture in sputum within 5 weeks before joining.

A részvétel fő kizáró okai

  • Another main lung disease besides bronchiectasis
  • Active tuberculosis, nontuberculous mycobacteria or allergic bronchopulmonary aspergillosis needing treatment
  • Need for long-term oxygen
  • Cancer now or within the past 5 years, with some exceptions
  • Pregnancy, breastfeeding, or AIDS or advanced HIV (CD4 count < 200 cells/mm3)

A regiszter feltételei, szó szerint

Mind a 21 feltétel megnézéseKevesebb

Ki vehet részt

  • Participant must be ≥ 18 years of age at the time of signing the informed consent/assent
  • Weight ≥ 35 kg
  • Bronchiectasis diagnosed by a physician and confirmed by CT demonstrating abnormal bronchial dilation in ≥ 1 lobe. Note: A historical CT scan within the past 5 years is acceptable. If not available, a CT scan should be conducted at screening to confirm eligibility
  • Participants who are receiving appropriate standard of care therapy per local guidelines and have a documented history of ≥ 2 moderate exacerbations or ≥ 1 severe exacerbation in the preceding 12 months requiring antibiotics
  • Participants who are clinically stable and free from an exacerbation of bronchiectasis for 4 weeks prior to randomization
  • Participants with pre- or post-bronchodilator FEV1 ≥ 25% predicted value at screening
  • Presence of positive (PCR or culture) PsA in an airway sample at least once in the last 24 months prior to screening
  • Presence of culture positive PsA in sputum at least within 5 weeks of randomization. Participants who have previously received PsA eradication therapy, as determined appropriate by their treating provider, but remain colonized with PsA are eligible for the study
  • Capable of giving signed informed consent/assent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol

Ki nem vehet részt

  • Evidence of active tuberculosis or active nontuberculous mycobacteria being treated or requiring treatment. Participants currently receiving treatment for active TB or nontuberculous mycobacteria may be considered after completion of an appropriate course of therapy
  • Malignancy, current or within the previous 5 years, except for stable prostate cancer, adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma in situ treated with apparent success more than one year prior to enrolment
  • Treatment with long term anti-PsA antibiotics, macrolides, or DPP-1 inhibitors, which are newly initiated within the 3 months prior to screening
  • Chronic immunosuppressive therapy (including prednisolone > 5 mg or equivalent) newly initiated within the last 3 months
  • Receipt of investigational products indicated for the treatment or prevention of bronchiectasis exacerbations or expected receipt during the study
  • Participation with a study intervention used within the last 30 days or 5 half-lives of the investigational product from the other clinical study, whichever is longer, prior to screening
  • Female participants who are pregnant, lactating, or WOCBP and not using a highly effective method of contraception or abstinence from at least 4 weeks prior to study intervention administration and until at least 6 months after study intervention administration
  • Evidence of an active allergic bronchopulmonary aspergillosis being treated or requiring treatment
  • History of severe adverse reaction associated with a mAb, and/or history of severe allergic reaction (eg, anaphylaxis that required the use of epinephrine/adrenaline or hospitalization), and/or history of immune complex disease (Type III hypersensitivity reactions) to monoclonal antibody administration
  • AIDS or Advanced human immunodeficiency virus disease (CD4 count of < 200 cells/mm3)
  • Primary lung diagnosis other than bronchiectasis
  • Need for long term supplemental oxygen. Oxygen use for ambulation and relief of breathlessness after exercise is allowed

Helyszínek itt: Kína

  • AnyangHospital not named in the registryRésztvevőt keres
  • BeijingHospital not named in the registryRésztvevőt keres
  • ChangshaHospital not named in the registryRésztvevőt keres
  • ChengduHospital not named in the registryRésztvevőt keres
  • ChizhouHospital not named in the registryRésztvevőt keres
  • HaikouHospital not named in the registryRésztvevőt keres
  • HefeiHospital not named in the registryRésztvevőt keres
  • HohhotHospital not named in the registryRésztvevőt keres
  • JinanHospital not named in the registryRésztvevőt keres
  • JinhuaHospital not named in the registryRésztvevőt keres
  • JiningHospital not named in the registryRésztvevőt keres
  • KunmingHospital not named in the registryRésztvevőt keres
  • LangfangHospital not named in the registryRésztvevőt keres
  • LinhaiHospital not named in the registryRésztvevőt keres
  • LiuzhouHospital not named in the registryRésztvevőt keres
  • NanchangHospital not named in the registryRésztvevőt keres
  • NanningHospital not named in the registryRésztvevőt keres
  • ShanghaiHospital not named in the registryRésztvevőt keres
  • ShenyangHospital not named in the registryRésztvevőt keres
  • TaicangHospital not named in the registryRésztvevőt keres
  • TaizhouHospital not named in the registryRésztvevőt keres
  • WenzhouHospital not named in the registryRésztvevőt keres
  • XinxiangHospital not named in the registryRésztvevőt keres
  • XuzhouHospital not named in the registryRésztvevőt keres
  • ZaozhuangHospital not named in the registryRésztvevőt keres
  • ZhangzhouHospital not named in the registryRésztvevőt keres
  • ZhengzhouHospital not named in the registryRésztvevőt keres
  • ZhuzhouHospital not named in the registryRésztvevőt keres
  • ZiboHospital not named in the registryRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.

A vizsgálat 2 csoportja

  • AZD0292A vizsgált kezelés

    AZD0292 administered starting on Day 1, subsequent administrations per schedule of assessments.

  • PlaceboPlacebo, összehasonlításként

    Placebo administered starting on Day 1, subsequent administrations per schedule of assessments.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase II Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. október 8.